Start Services Company Profile Publications Jobs Customers Contact

vivacell_graurotbuttonklein  Recent news

September 2016

Cooperation with Dhofar University (Sultanate of Oman)

 

May 2016

We were awarded the Stifterverband's "Innovative through Research" for our research activities.

 

April 2016

New Version of SimDerma including 30 important dermato-cosmetic parameters.

Read more here.

 

November 2015:

New Services in neurotoxicity and neuroprotection

Read more here.

 

October 2015:

SimDerma - new screening platform for cosmetic ingredients.

simderma_werbefoto

Read more here.

 

Services in Oral Care.

Read more here.

 

September 2015:

Please have a look at our new services in miRNA research.

Read more here.

 


 

New publications by VivaCell:

 

"Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary
microglia."

in J Neuroinflamm. 2016 Jan

 

"Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia
Through Nrf2-Dependent Mechanisms."

in Mol Neurobiol. 2015 Nov

 

"microRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia."

in J Neurochem, 2015 Sep

 

"Anti-inflammatory effects of 5-HT3 receptor antagonists in interleukin-1beta stimulated primary human chondrocytes."
in Int Immunopharmacol. 2014 Jun

"Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia."
Neuroscience. 2014 Jan 28

 

 

Read more news...

 

 

vivacell_graurotbuttonklein  Opinions from our customers:

p-pascoe-naturmedizin

Dr. G. Weiss (PASCOE pharmazeutische Praeparate GmbH):

:

"During our well going cooperation over several years, we learned to appreciate VivaCell as a reliable and competent co-operation partner in pre-clinical research. Therefore we are looking forward to continue our successful partnership."  

 

 

Read more
opinions...

 

 

Team
Mission
Expertise
Partner
Cooperation with Dhofar Uni

 

We are awarded for our R&D activities by the Stifterverband:

 

forschung_und_entwicklung_2016_web

 

 


 

We are proud members of:

 

logo_biovalley

    koop-phyto-logo

ga 

 

logo_bpl-rgb_klein-web

 


 

VivaCell Quality-Certificate:

 

vivacellqualitycertificateenglish

 

Read more ...

 portrait_dr_bernd_fiebich_vivacell_n  

Bernd L. Fiebich, Ph.D. (CEO)

 

Bernd L. Fiebich is CEO and co-founder of VivaCell.

 

He is an expert in peripheral and central immunology and inflammatory diseases, Ass. prof., since 1994.

 

Bernd L. Fiebich is an internationally leading scientist in the field of prostaglandins and cyclooxygenase-1/-2. He works in the field of natural products for many years, especially on analgesic and anti-inflammatory effects of phytomedicines (e.g. Harpagophytum).

 

He established a variety of cellular models of pain and inflammation

for the periphery (e.g. monocytes) or the CNS (neuronal cells, microglia:

e.g. with vitamin C, caffeine, Petasites). Guided many projects in the field of phytodrug development e.g. Harpagophytum.


His list of publications is available here:
http://www.ncbi.nlm.nih.gov/pubmed?term=Fiebich+B

 

portrait_appel

Kurt Appel, Ph. D. (CEO)

 

Kurt Appel is CEO of VivaCell Biotechnology GmbH since 2001.

 

Specialised on safety aspects of natural products Dr. Appel managed various safety studies with natural products (Harpagophytum, Hypericum, Passiflora, St. John’s Wort etc.) over the last years.

 

Before Dr. Appel joined VivaCell he was the responsible scientist (CRO) in

the field of metabolism and drug interaction for about a decade and head of the “BSE Labor Südwest”.

 

 

munoz_portrait2013

 

Prof. Eduardo Munoz, M.D, Ph.D. (VivaCell Biotechnology España)

 

Professor of Immunology of the Department of Cell Biology, Physiology and Immunology of the University of Córdoba. PhD in Medicine and Surgery at the University of Córdoba (1986), he was an associate researcher at Tufts University (Boston, 1987-90), and at the Institut Pasteur (Paris, 1992-94).

 

Prof. Muñoz has been involved in several projects aimed at evaluating the biological effects of natural and synthetic compounds on different analgesic/anti-inflammatory and anti-HIV molecular targets and he is the author of more than 130 articles published in international scientific journals.

 

Prof. Muñoz belongs to the editorial board of the scientific journals Planta Medica (Thieme publishers, DE), Advances in Pharmaceutical Sciences (Hindawi Publishing Corporation) and Fitoterapia (Elsevier). In 2009 he was given the Exxentia International Award for Applied Research in Phytotherapy and Nutrition. Prof. Muñoz is co-founder of two biotech companies located in Spain (VivaCell Biotechnology España SL) and Sweden (Glacton Pharma AB) and he is a member of the SAB at Aphios Corporation (USA)

 

   

 

 

 

 

 

       Sprache         Language          Idioma

germanenglishspanish